<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Osteosarcoma: Epidemiology, pathology, clinical presentation, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Osteosarcoma: Epidemiology, pathology, clinical presentation, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Osteosarcoma: Epidemiology, pathology, clinical presentation, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lisa L Wang, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark C Gebhardt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nino Rainusso, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alberto S Pappo, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raphael E Pollock, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth H Baldini, MD, MPH, FASTRO</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Osteosarcoma is a rare primary malignant tumor of bone that is characterized by an osteoid matrix produced by the malignant cells [<a href="#rid1">1</a>]. Osteosarcoma is an uncommon tumor and accounts for less than 1 percent of all cancers diagnosed annually in the United States and 3 percent of all childhood cancers [<a href="#rid2">2</a>]. The survival of patients with osteosarcoma improved dramatically after the introduction of multimodality therapy, including systemic chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/7723.html" rel="external">"Chemotherapy and radiation therapy in the management of osteosarcoma", section on 'Prognosis and evolution of treatment'</a>.)</p><p>The epidemiology, pathology, clinical presentation, and diagnosis of osteosarcoma are reviewed here. Diagnosis and biopsy techniques for primary bone tumors, principles guiding surgical management of bone sarcomas, and the management of osteosarcoma are discussed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7741.html" rel="external">"Bone tumors: Diagnosis and biopsy techniques"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7739.html" rel="external">"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7723.html" rel="external">"Chemotherapy and radiation therapy in the management of osteosarcoma"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence </strong>– Osteosarcoma is an uncommon tumor. Approximately 1000 new cases are diagnosed each year in the United States, of which 500 cases arise in children and adolescents younger than 20 years of age [<a href="#rid2">2</a>]. Despite its rarity, osteosarcoma is the most common primary malignancy of bone in children as well as adolescents and young adults (AYAs) aged 15 to 19 [<a href="#rid2">2,3</a>]. Among individuals with bone cancer under the age of 20, osteosarcoma comprises 56 percent of all cases, followed by Ewing sarcoma (34 to 36 percent), and chondrosarcoma (less than 10 percent). (See  <a class="medical medical_review" href="/z/d/html/7742.html" rel="external">"Epidemiology, pathology, and molecular genetics of Ewing sarcoma"</a> and  <a class="medical medical_review" href="/z/d/html/7724.html" rel="external">"Chondrosarcoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> –<strong> </strong>There is a bimodal age distribution for the incidence of osteosarcoma. Among children and AYAs, the peak incidence is between 13 and 16 years of age, a time that appears to coincide with the adolescent growth spurt [<a href="#rid4">4</a>]. Osteosarcoma also occurs at an earlier age in female children, corresponding to their more advanced skeletal age and earlier adolescent growth spurt compared with male children. (See <a class="local">'Pathogenesis'</a> below.)</p><p></p><p class="bulletIndent1">In adults, the peak incidence occurs over the age of 65  (<a class="graphic graphic_figure graphicRef81466" href="/z/d/graphic/81466.html" rel="external">figure 1</a>) [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex </strong>– Osteosarcoma is slightly more predominant in males than females (ratio of 1.4:1), both in children and in adults [<a href="#rid5">5-7</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethnicity </strong>– Among children, osteosarcoma occurs more frequently in Black individuals and other ethnicities compared with White individuals [<a href="#rid5">5,8-10</a>]. Among adults, in contrast to children, osteosarcoma is more common in White individuals than in Black individuals or individuals of other ethnicities [<a href="#rid5">5,6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Geographic incidence </strong>– The incidence of osteosarcoma in children differs geographically. Some regions of Africa, South Asia, and Central and South America are estimated to have twice the number of new cases of osteosarcoma compared with North America or Europe [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1">Among adults over the age of 60 in the United States, where Paget disease (a risk factor for osteosarcoma) is common, secondary tumors are more common than primary tumors [<a href="#rid6">6,12</a>]. In other countries where Paget disease is less frequent, such as Japan and other countries in Eastern Asia, osteosarcoma arises more commonly as a primary tumor among patients over the age of 40 [<a href="#rid13">13,14</a>]. (See <a class="local">'Paget disease and other benign bone processes'</a> below.)</p><p></p><p class="headingAnchor" id="H5"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Several risk factors for osteosarcoma have been identified as follows:</p><p class="headingAnchor" id="H7"><span class="h2">Radiation and chemotherapy</span><span class="headingEndMark"> — </span>Osteosarcoma that occurs in the setting of prior radiation and chemotherapy is classified as a secondary osteosarcoma [<a href="#rid1">1,15</a>]. (See <a class="local">'Secondary osteosarcoma'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy </strong>– Osteosarcoma is the most common secondary malignant neoplasm (ie, subsequent primary cancer) to occur during the first 20 years following radiation therapy (RT) for a solid cancer in childhood. Data suggest that approximately 3 percent of osteosarcomas could be attributed to prior irradiation, although the incidence may increase as cancer survivors treated with RT live long enough to potentially develop this complication. The interval between irradiation and the appearance of a secondary osteosarcoma averages 12 to 16 years; this interval is shorter in childhood cancer survivors. (See  <a class="medical medical_review" href="/z/d/html/14261.html" rel="external">"Radiation-associated sarcomas", section on 'Epidemiology and histologic distribution'</a> and  <a class="medical medical_review" href="/z/d/html/14261.html" rel="external">"Radiation-associated sarcomas", section on 'Radiation dose and age of exposure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemotherapy </strong>– Prior exposure to chemotherapy, particularly alkylating agents, is also associated with subsequent primary osteosarcoma in childhood cancer survivors and may potentiate the effect of previous RT. (See  <a class="medical medical_review" href="/z/d/html/14261.html" rel="external">"Radiation-associated sarcomas", section on 'Chemotherapy agents'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Paget disease and other benign bone processes</span><span class="headingEndMark"> — </span>Osteosarcoma that arises in patients older than 40 years of age can be associated with Paget disease, a focal skeletal disorder characterized by an accelerated rate of bone turnover  (<a class="graphic graphic_diagnosticimage graphicRef55541" href="/z/d/graphic/55541.html" rel="external">image 1</a>) [<a href="#rid16">16</a>]. Although the incidence of bone tumors is markedly increased in patients with Paget disease, they only occur in 0.7 to 1 percent of cases [<a href="#rid17">17</a>]. Osteosarcoma arising in the setting of Paget disease is typically associated with a worsened prognosis [<a href="#rid18">18</a>].</p><p>Tumor involvement of multiple sites of bone is common in these patients. Osteosarcoma in the setting of Paget disease arises from pagetic bone, which can be seen on imaging and confirmed on histology. Otherwise, osteosarcoma associated with Paget disease is histologically indistinguishable from osteosarcomas in patients without Paget disease. Although sarcomatous transformation is most often seen in long-standing Paget disease, it is not necessarily related to the extent of skeletal involvement. (See  <a class="medical medical_review" href="/z/d/html/5601.html" rel="external">"Clinical manifestations and diagnosis of Paget disease of bone"</a>.) </p><p>It is unclear how Paget disease leads to the development of osteosarcoma, but genetic factors are thought to play a role. Both Paget disease and osteosarcoma in the setting of Paget disease have been associated with loss of heterozygosity of chromosome 18, possibly involving the same site of a postulated tumor suppressor gene [<a href="#rid19">19,20</a>], as well as presence of somatic pathogenic variants in the <em>SQSTM1</em> gene on chromosome 5q35 [<a href="#rid21">21</a>].</p><p>In addition to Paget disease, other benign bone lesions are associated with an increased risk of malignant degeneration to a primary bone tumor. These include chronic osteomyelitis; sites of bone infarcts; and benign bone lesions such as fibrous dysplasia, which can be seen in those with McCune-Albright syndrome [<a href="#rid22">22,23</a>]. There are also reports of osteosarcoma arising in benign bone tumors treated with curettage and bone grafts [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/6294.html" rel="external">"Nonmalignant bone lesions in children and adolescents", section on 'Fibrous dysplasia'</a> and  <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty", section on 'McCune-Albright syndrome'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Genetic conditions</span><span class="headingEndMark"> — </span>Patients with osteosarcoma, particularly children, may have a genetic predisposition to the disease. The frequency of a germline pathogenic variant among those with osteosarcoma ranges between 18 and 28 percent in observational studies [<a href="#rid25">25,26</a>]. The majority of pathogenic variants are in the <em>RB1</em> (the gene associated with hereditary retinoblastoma) and <em>TP53</em> (the gene associated with Li-Fraumeni syndrome [LFS]) genes. Other pathogenic variants have also been identified such as autosomal dominant cancer susceptibility genes including <em>APC</em>, <em>PALBB2</em>, and <em>MSH2</em>, as well as <em>CDKN2A</em>, <em>ATRX</em>, <em>MEN1</em>, and <em>POT1</em>, among others [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">"Pathogenetic factors in soft tissue and bone sarcomas"</a>.)</p><p>In patients with newly diagnosed osteosarcoma, particularly those with multiple primary malignancies, it is important to obtain a detailed family history to assess for predisposing genetic conditions [<a href="#rid27">27</a>]. Patients may be referred for genetic consultation and testing as clinically appropriate. (See  <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p class="headingAnchor" id="H4246276211"><span class="h3">Retinoblastoma</span><span class="headingEndMark"> — </span>The genetic abnormality that causes hereditary retinoblastoma (germline pathogenic variants of the <em>RB1</em> gene) is also associated with an increased risk of developing subsequent primary tumors. Among these tumors, approximately 60 percent are soft tissue sarcomas and osteosarcoma [<a href="#rid28">28-31</a>]. (See  <a class="medical medical_review" href="/z/d/html/6275.html" rel="external">"Retinoblastoma: Clinical presentation, evaluation, and diagnosis", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/14261.html" rel="external">"Radiation-associated sarcomas", section on 'Genetic predisposition'</a>.)</p><p>Patients with hereditary retinoblastoma are at much higher risk of developing osteosarcoma compared with those with nonhereditary (sporadic) disease. Patients with retinoblastoma who receive RT are also at higher risk for developing osteosarcoma later in life, not only within irradiated fields but also in long bones distant from radiation fields. These data are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">"Pathogenetic factors in soft tissue and bone sarcomas", section on 'Retinoblastoma'</a>.)</p><p class="headingAnchor" id="H3357215535"><span class="h3">Li-Fraumeni syndrome</span><span class="headingEndMark"> — </span>Patients with LFS are at risk for developing osteosarcoma, although the incidence is low [<a href="#rid32">32-37</a>]. LFS is a familial cancer syndrome associated with germline pathogenic variants in the<em> TP53</em> tumor suppressor gene, which is involved in cell cycle regulation and maintaining the integrity of the genome. Patients with LFS display a spectrum of cancers, including breast, soft tissue, adrenocortical, and brain tumors; leukemias; and osteosarcoma [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">"Li-Fraumeni syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">"Pathogenetic factors in soft tissue and bone sarcomas", section on 'Li-Fraumeni syndrome'</a>.)</p><p class="headingAnchor" id="H4015167854"><span class="h3">Other genetic conditions</span><span class="headingEndMark"> — </span>Besides hereditary retinoblastoma and LFS, other genetic conditions with a known predisposition to osteosarcoma include Rothmund-Thomson syndrome (RTS), RAPADILINO, and the related Bloom and Werner syndromes. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rothmund-Thomson syndrome </strong>– RTS is an autosomal recessive condition characterized by distinctive skin findings (atrophy, telangiectasias, pigmentation), sparse hair, cataracts, small stature, skeletal anomalies, and a significantly increased risk for osteosarcoma [<a href="#rid38">38,39</a>]. In one cohort of 41 patients with RTS, 13 (32 percent) developed osteosarcoma [<a href="#rid38">38</a>]. Clinically, these tumors tend to develop at a younger age than seen in the general population. (See  <a class="medical medical_review" href="/z/d/html/15510.html" rel="external">"Kindler epidermolysis bullosa", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/15466.html" rel="external">"Xeroderma pigmentosum", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1">Loss of function pathogenic variants in the <em>RECQL4</em> gene have been identified in approximately two-thirds of patients with RTS and are closely associated with the risk for osteosarcoma. In one series of 33 patients with RTS, none of the 10 patients without a pathogenic variant in this gene developed osteosarcoma, while among the 23 patients with a pathogenic variant in <em>RECQL4</em>, the incidence of osteosarcoma was five cases per year with 230 person-years of observation [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RAPADILINO </strong>– RAPADILINO is an allelic disorder with many overlapping features with RTS and is also caused by pathogenic variants in the <em>RECQL4</em> gene. In addition to increased risk of osteosarcoma, these patients are also at higher risk of developing lymphoma [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bloom syndrome and Werner syndrome </strong>– Other members of the <em>RECQ</em> gene family are mutated in Bloom syndrome (<em>BLM</em> gene) and Werner syndrome (<em>WRN</em> gene), two diseases with overlapping clinical features, including a predisposition to develop osteosarcoma [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/3959.html" rel="external">"Bloom syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/106742.html" rel="external">"Werner syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H803659779"><span class="h2">PTH and PTHrp analog therapy</span><span class="headingEndMark"> — </span>In patients with osteoporosis, parathyroid hormone (PTH) and/or parathyroid hormone-related protein (PTHrP) analog therapy is contraindicated in those who are also at increased baseline risk for osteosarcoma. (See <a class="local">'Risk factors'</a> above and  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Contraindications/precautions'</a>.)</p><p>Preclinical studies suggest that PTH and/or PTHrP analog therapy is associated with an increased risk of osteosarcoma. Although limited observational studies in humans have not supported this association, long-term follow-up data are necessary to confirm. Further details on the safety of these osteoporosis treatments are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Long-term risks'</a>.)</p><p class="headingAnchor" id="H469099193"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Osteosarcoma appears to originate from bone-forming stem or progenitor cells that reside in the skeleton [<a href="#rid42">42</a>]. However, the specific molecular alterations in these cells that lead to tumor development remain elusive. Identifying molecular alterations that can be targeted for therapeutic purposes remains an active area of investigation [<a href="#rid43">43</a>]. Rapid bone growth may also play a role in the pathogenesis of osteosarcoma. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular alterations</strong> – Osteosarcoma tumors are characterized by highly complex karyotypes. This molecular finding may occur because of the "chromothripsis" phenomenon, where a single catastrophic cellular event causes a chaotic chromosomal rearrangement [<a href="#rid44">44,45</a>]. Although there is no characteristic translocation driving the process of oncogenesis, as occurs in other sarcomas, osteosarcoma tumors have recurrent amplifications or deletions in some chromosomal regions. The highest frequency of chromosomal deletions in osteosarcoma has been reported in regions of 3q and 13q (the location of the <em>RB</em> gene), 17p (the location of the <em>TP53 </em>gene), and 18q (the location linked to osteosarcoma arising in the setting of Paget disease) [<a href="#rid46">46</a>]. Combined inactivation of the <em>RB</em> and <em>TP53</em> pathways is common in osteosarcoma. Moreover, genomic alterations in <em>TP53</em> and <em>RB</em> may arise due to gene deletion, pathogenic variants, or structural variations [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1">Recurrent amplifications of various chromosomal regions have also been observed in osteosarcoma. The genetic region 8q contains the gene <em>MYC</em>, which is amplified in up to half of cases of osteosarcoma and may be associated with a poor prognosis [<a href="#rid47">47</a>]. Amplification of <em>FGFR1</em> and alterations in the <em>IGF1R</em> pathway have also been observed in about 18.5 and 14 percent of cases, respectively [<a href="#rid43">43,48</a>]. The <em>PIK3</em>/<em>mTOR</em> pathway has also been found to be altered in one-fourth of patients. Mutations or loss of <em>PTEN</em> are the most common alteration reported in this pathway [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">Other molecular alterations have also been demonstrated in genes such as isocitrate dehydrogenase (<em>IDH1</em> and <em>IDH2</em>) for conventional chondrosarcoma; <em>MDM2</em> in parosteal and low-grade central osteosarcoma; <em>DLG2, ATRX, CDK4, </em>and<em> VEGFR</em> [<a href="#rid50">50,51</a>]. The influence of these genes as well as other molecular pathways (such as the Wnt, Notch, insulin-like growth factor [IGF] pathways) is beyond the scope of this topic [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapid bone growth</strong> – The development of osteosarcoma may be related to rapid bone growth, since the peak incidence of disease occurs during the adolescent growth spurt [<a href="#rid4">4</a>]. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1">The tumor also appears most frequently at sites where the greatest increase in bone length and size occurs (eg, the metaphyseal portions of the distal femur, proximal tibia, and proximal humerus  (<a class="graphic graphic_figure graphicRef76662" href="/z/d/graphic/76662.html" rel="external">figure 2A</a>)). (See <a class="local">'Tumor location'</a> below.)</p><p></p><p class="bulletIndent1">This process is thought to occur due to an aberration of the normal process of bone growth and remodeling; this is a time when rapidly proliferating cells are particularly susceptible to oncogenic agents, mitotic errors, or other events leading to neoplastic transformation [<a href="#rid52">52</a>]. However, the precise etiology of osteosarcoma development remains unclear, and studies examining the relationship between growth and developmental factors (including height) and the risk of bone sarcomas have revealed no consistent pattern [<a href="#rid53">53-55</a>].</p><p></p><p class="headingAnchor" id="H1161898229"><span class="h1">HISTOLOGIC CLASSIFICATION</span></p><p class="headingAnchor" id="H3426588109"><span class="h2">Approach to histologic diagnosis</span><span class="headingEndMark"> — </span>The 2020 World Health Organization classification of bone tumors recognizes the following osteosarcoma subtypes: </p><p class="bulletIndent1"><span class="glyph">●</span>Low-grade central osteosarcoma (see <a class="local">'Low-grade central osteosarcoma'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Osteosarcoma not otherwise specified (NOS), which includes (see <a class="local">'Osteosarcoma not otherwise specified'</a> below):</p><p class="bulletIndent2"><span class="glyph">•</span>Conventional osteosarcoma (see <a class="local">'Conventional osteosarcoma'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Telangiectatic osteosarcoma (see <a class="local">'Telangiectatic osteosarcoma'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Small cell osteosarcoma (see <a class="local">'Small cell osteosarcoma'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parosteal osteosarcoma (see <a class="local">'Parosteal osteosarcoma'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Periosteal osteosarcoma (see <a class="local">'Periosteal osteosarcoma'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-grade surface osteosarcoma (see <a class="local">'High-grade surface osteosarcoma'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary osteosarcoma (see <a class="local">'Secondary osteosarcoma'</a> below)</p><p></p><p>The histopathologic diagnosis of osteosarcoma is based on morphology and the presence of malignant cells that form new bone (osteoid). In some tumors with a limited degree of osteoid production and variable histomorphology, immunohistochemistry may be required for confirmation of the diagnosis. However, in contrast to other sarcomas, there are no specific immunostains or molecular tests for osteosarcoma, since it is not associated with any characteristic immunoprofile or chromosomal translocations. (See  <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">"Pathogenetic factors in soft tissue and bone sarcomas"</a>.)</p><p class="headingAnchor" id="H4088162546"><span class="h2">Low-grade central osteosarcoma</span><span class="headingEndMark"> — </span>Low-grade central osteosarcoma only accounts for 1 to 2 percent of all osteosarcomas. This slow-growing tumor occurs in young adults and arises in the metaphysis of long bones [<a href="#rid56">56</a>]. Histologically, it is characterized by low mitotic activity of spindle cells in well-formed neoplastic bone. Amplification of <em>MDM2</em> and <em>CDK4</em> is common [<a href="#rid57">57</a>]. Approximately 10 to 36 percent of cases may progress to high-grade sarcoma. Treatment for low-grade central osteosarcoma is typically surgical resection alone, with survival rates of approximately 90 percent [<a href="#rid58">58</a>]. </p><p class="headingAnchor" id="H3736106726"><span class="h2">Osteosarcoma not otherwise specified</span><span class="headingEndMark"> — </span>Osteosarcoma NOS includes conventional, telangiectatic, and small cell osteosarcoma. The age distribution and treatment are similar for the various osteosarcoma NOS. </p><p class="headingAnchor" id="H3568978108"><span class="h3">Conventional osteosarcoma</span><span class="headingEndMark"> — </span>The largest group is conventional osteosarcoma which accounts for approximately 90 percent of all osteosarcomas [<a href="#rid59">59,60</a>]. These tumors arise in the intramedullary region and typically involve the metaphysis of long bones  (<a class="graphic graphic_figure graphicRef76662" href="/z/d/graphic/76662.html" rel="external">figure 2A</a>).</p><p>Depending on the predominant cellular component, conventional osteosarcomas are subclassified as osteoblastic (accounting for 76 to 80 percent), chondroblastic (10 to 13 percent), or fibroblastic (10 percent) [<a href="#rid61">61,62</a>]. Despite histologic differences, their clinical behavior and management are similar.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteoblastic osteosarcoma</strong> – Osteoblastic osteosarcoma is characterized by abundant production of an osteoid and woven bone matrix in association with malignant tumor cells, which forms a fine or coarse lacelike pattern around the tumor cells; massive amounts may result in distortion of the malignant stromal cells  (<a class="graphic graphic_picture graphicRef87011" href="/z/d/graphic/87011.html" rel="external">picture 1</a>). Some tumors contain thick trabeculae of osteoid matrix that form an irregular anastomosing network. The degree of mineralization is variable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibroblastic osteosarcomas </strong>– Fibroblastic osteosarcoma is predominantly composed of a high-grade spindle cell stroma that contains only focal areas of bone production  (<a class="graphic graphic_picture graphicRef87013" href="/z/d/graphic/87013.html" rel="external">picture 2</a>). More pleomorphic tumors may resemble undifferentiated high-grade pleomorphic sarcoma of bone (previously known as malignant fibrous histiocytoma of bone), but the distinction can be made by the identification of an osteoid matrix produced by the tumor rather than reactive periosteal host woven bone, which may be present at the periphery of the tumor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chondroblastic osteosarcoma </strong>– In chondroblastic osteosarcoma, cartilaginous matrix production is evident throughout most of the tumor. While the majority of the tumor tends to be of lower grade, the chondroid areas may contain cytologically atypical cells that are characteristic of higher grade tumors. These chondroblastic foci are admixed with malignant spindle cells that produce bony trabecula  (<a class="graphic graphic_picture graphicRef87012" href="/z/d/graphic/87012.html" rel="external">picture 3</a>).</p><p></p><p class="headingAnchor" id="H1934167377"><span class="h3">Telangiectatic osteosarcoma</span><span class="headingEndMark"> — </span>Telangiectatic osteosarcoma is a high-grade, vascular tumor that contains little osteoid [<a href="#rid63">63</a>]. Because of its radiolucent appearance on plain radiographs, telangiectatic osteosarcoma can be confused with aneurysmal bone cysts or giant cell tumors of bone (GCTB). Grossly they appear as a "multicystic bag of blood," and a solid mass of tumor is usually absent [<a href="#rid59">59</a>]. As a result, it may be difficult to obtain diagnostic tissue on biopsy. Histologically, the minimal osteoid or woven bone formation and numerous multinucleated giant cells  (<a class="graphic graphic_picture graphicRef87014" href="/z/d/graphic/87014.html" rel="external">picture 4</a>) are reminiscent of a benign GCTB. However, the cells are highly pleomorphic. (See  <a class="medical medical_review" href="/z/d/html/7731.html" rel="external">"Giant cell tumor of bone"</a>.)</p><p>In general, the prognosis of patients with telangiectatic osteosarcoma is similar to or more favorable than those with the conventional chondroblastic subtype of osteosarcoma [<a href="#rid64">64,65</a>]. (See <a class="local">'Conventional osteosarcoma'</a> above.)</p><p class="headingAnchor" id="H922531326"><span class="h3">Small cell osteosarcoma</span><span class="headingEndMark"> — </span>Small cell osteosarcoma is noteworthy for the confusion that may arise in its distinction from other "small round blue cell tumors" such as Ewing sarcoma by conventional light microscopy of hematoxylin and eosin stained sections [<a href="#rid66">66,67</a>]. Small cell osteosarcoma contains small cells with scant cytoplasm, round nuclei, and coarse chromatin, associated with osteoid production. Immunohistochemical staining, cytogenetics, and molecular genetic studies may be required to distinguish this osteosarcoma subtype from Ewing sarcoma [<a href="#rid68">68,69</a>]. (See  <a class="medical medical_review" href="/z/d/html/7744.html" rel="external">"Clinical presentation, staging, and prognostic factors of Ewing sarcoma", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H3755380095"><span class="h2">Parosteal osteosarcoma</span><span class="headingEndMark"> — </span>Parosteal osteosarcoma is a surface lesion composed of low-grade fibroblastic cells that produce woven bone that sometimes has a lamellar appearance. It occurs in an older age group than conventional osteosarcoma, usually between the ages of 20 and 40 years. The posterior aspect of the distal femur is the most commonly involved site, but other long bones may be affected. The tumor arises from the cortex as a broadly based lesion. With time, however, this lesion may invade the cortex and enter the endosteal cavity. </p><p>For parosteal osteosarcoma, the prognosis is relatively good with surgical resection alone, as survival rates are approximately 90 percent [<a href="#rid70">70,71</a>]. In contrast, dedifferentiated parosteal osteosarcoma is a variant in which a high-grade sarcoma component exists along with the parosteal osteosarcoma. Dedifferentiated parosteal sarcoma occurs in 15 to 43 percent of cases; these patients present with more aggressive disease and both surgery and chemotherapy are often administered [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H1871487992"><span class="h2">Periosteal osteosarcoma</span><span class="headingEndMark"> — </span>Periosteal osteosarcoma is an intermediate-grade, chondroblastic surface osteosarcoma that is frequently located in the proximal tibia; it has the same age distribution as conventional osteosarcoma. Observational studies indicate more favorable outcomes than that seen with conventional osteosarcoma (10-year survival rate of 84 percent [<a href="#rid73">73</a>]). However, the likelihood of metastases is approximately 20 percent, which is higher than that for the low-grade parosteal tumors, but lower than that for conventional osteosarcomas. </p><p>Adjuvant chemotherapy is recommended in many centers because of the estimated 20 percent metastatic rate. However, the role of adjuvant chemotherapy for periosteal osteosarcoma is controversial due to [<a href="#rid73">73</a>] lack of benefit when patients who received adjuvant chemotherapy were compared with those treated by surgery alone [<a href="#rid73">73,74</a>] and a concerning number of subsequent primary cancers in patients treated with adjuvant chemotherapy [<a href="#rid73">73</a>]. In part because of its rarity, randomized trials have not been conducted to address this issue, which limits the conclusions that can be drawn from the available literature.</p><p class="headingAnchor" id="H2149394873"><span class="h2">High-grade surface osteosarcoma</span><span class="headingEndMark"> — </span>High-grade osteosarcoma may also develop on the surface of the bone, where it may be confused with parosteal or periosteal osteosarcoma. These tumors are treated similarly to conventional osteosarcoma that arises in the intramedullary portion of the bone. (See <a class="local">'Conventional osteosarcoma'</a> above.)</p><p class="headingAnchor" id="H1963224093"><span class="h2">Secondary osteosarcoma</span><span class="headingEndMark"> — </span>Secondary osteosarcoma is osteosarcoma that develops in abnormal bone. The most common causes of secondary osteosarcoma are Paget disease of the bone and prior exposure to radiation. (See <a class="local">'Risk factors'</a> above.)</p><p>The median dose of radiation therapy (RT) associated with secondary osteosarcoma is 50 Gy [<a href="#rid75">75</a>]. This tumor is histologically indistinguishable from conventional osteosarcoma. However, the prognosis of secondary osteosarcoma is worse than that of conventional osteosarcoma [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1375115785"><span class="h2">Rarer variants</span></p><p class="headingAnchor" id="H96372219"><span class="h3">Multifocal osteosarcoma</span><span class="headingEndMark"> — </span>Rarely, patients present with multiple synchronous sites at diagnosis, all resembling the primary tumor. It is difficult to determine whether these represent multiple synchronous primary lesions or are considered metastases. Regardless of their designation, the prognosis is usually poor, although a few patients may achieve significant life prolongation under current treatment approaches [<a href="#rid76">76</a>]. Multifocal osteosarcoma may also be metachronous in that other bony lesions occur years after treatment of the first.</p><p class="headingAnchor" id="H2292475523"><span class="h3">Craniofacial osteosarcoma</span><span class="headingEndMark"> — </span>Craniofacial osteosarcoma is another distinct variant which tends to occur in older patients and may have a more indolent course. Patients with craniofacial osteosarcoma are more likely to have local recurrence than distant metastases; this may be attributed to different tumor biological behavior from other osteosarcomas as well as difficulty obtaining wide surgical margins in this anatomically challenging location. The mandible and maxilla are the most common primary sites for craniofacial osteosarcoma [<a href="#rid77">77</a>]. </p><p>The management of craniofacial osteosarcoma primarily includes surgical resection [<a href="#rid78">78-80</a>]. The use of chemotherapy and radiation for craniofacial osteosarcoma are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3367.html" rel="external">"Head and neck sarcomas", section on 'Osteosarcoma'</a>.) </p><p class="headingAnchor" id="H11"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H431088108"><span class="h2">Primary versus secondary neoplasms</span><span class="headingEndMark"> — </span>Children and adolescents and young adults (AYAs) with osteosarcoma most frequently present with a primary, sporadic neoplasm. Those with an inherited predisposition to osteosarcoma account for a minority of patients. (See <a class="local">'Genetic conditions'</a> above.)</p><p>In contrast, secondary osteosarcoma are primarily observed among adults. Such secondary neoplasms are attributed to sarcomatous transformation of Paget disease of bone, secondary sarcomas in irradiated bone, bone infarcts, or some other benign bone lesions [<a href="#rid5">5,12</a>]. (See <a class="local">'Paget disease and other benign bone processes'</a> above and  <a class="medical medical_review" href="/z/d/html/14261.html" rel="external">"Radiation-associated sarcomas"</a>.)</p><p class="headingAnchor" id="H1115639111"><span class="h2">Tumor location</span></p><p class="headingAnchor" id="H3758995663"><span class="h3">Primary tumor</span><span class="headingEndMark"> — </span>The initial presenting site of the primary tumor differs according to age at presentation.</p><p>The most common sites of osteosarcoma in children are the metaphyses of long bones  (<a class="graphic graphic_figure graphicRef76662 graphicRef50795" href="/z/d/graphic/76662.html" rel="external">figure 2A-B</a>). The most common sites of involvement, in descending order, are [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Distal femur (32 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Proximal tibia (19 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Proximal humerus (10 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Middle and proximal femur (10 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Other bones, such as the mandible (8 percent) and pelvis (8 percent)</p><p></p><p>Tumors involving the axial and craniofacial bones are more commonly seen in adults than children. However, adults can also still present with disease in the lower extremity bones, similarly to children [<a href="#rid5">5,6</a>]. Adults also are more likely to present with osteosarcoma in areas that have been previously treated with radiation therapy (RT) or that have underlying bone abnormalities. (See <a class="local">'Risk factors'</a> above.)</p><p class="headingAnchor" id="H3307805478"><span class="h3">Distant metastases</span><span class="headingEndMark"> — </span>At the time of presentation, between 10 and 20 percent of patients have demonstrable macrometastatic disease. Adults over the age of 60 years at diagnosis are also at higher risk for metastatic disease at presentation. Metastatic disease occurs most frequently in the lungs, followed by the other bones [<a href="#rid81">81</a>]. (See  <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Pattern of spread'</a>.)</p><p>Metastases can also involve the same bone or a different bone [<a href="#rid82">82</a>]. Approximately 1 to 6 percent of patients present with "skip" metastases  (<a class="graphic graphic_diagnosticimage graphicRef121740" href="/z/d/graphic/121740.html" rel="external">image 2</a>), or synchronous smaller foci of tumor anatomically separated from the primary lesion, either in the same bone or in the opposing site of a joint (transarticular  (<a class="graphic graphic_diagnosticimage graphicRef121740" href="/z/d/graphic/121740.html" rel="external">image 2</a>)). Bony metastases in the same bone or the bone adjacent to the primary tumor are associated with a worse prognosis [<a href="#rid83">83,84</a>]. (See <a class="local">'Evaluation for systemic disease'</a> below.)</p><p class="headingAnchor" id="H590129815"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>The majority of patients with osteosarcoma present with localized pain at the primary tumor site, typically of several weeks' duration. Pain often begins after an injury and may wax and wane over time. Systemic symptoms such as fever, weight loss, and malaise are generally absent.</p><p>Pain may also be related to a pathologic fracture, which may be present in approximately 12 percent of patients with osteosarcoma at diagnosis [<a href="#rid65">65</a>]. Due to the potential risk of pathologic fracture, patients with suspected osteosarcoma are typically advised to limit or use protective weight bearing on the affected limb. (See  <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">"Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma"</a>.)</p><p class="headingAnchor" id="H2712224777"><span class="h2">Physical exam</span><span class="headingEndMark"> — </span>The most noticeable finding on physical examination is a soft tissue mass, which is frequently large and tender to palpation. The mass may exhibit increased vascularity of the skin. Patients may demonstrate decreased range of motion of the affected limb or walk with a limp if the tumor involves one of the lower extremities. Patients may also have increased regional lymphadenopathy. Masses are more difficult to detect in patients with pelvic osteosarcoma. Since systemic symptoms are generally absent, patients with pulmonary metastases may still present with a normal respiratory exam. </p><p class="headingAnchor" id="H12"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H1804275099"><span class="h2">Plain radiograph</span><span class="headingEndMark"> — </span>The first diagnostic test in patients with suspected osteosarcoma is generally a plain radiograph of the primary tumor [<a href="#rid62">62</a>]. It is important to obtain radiographs of the entire involved bone. </p><p>Characteristic features on plain radiograph of conventional osteosarcoma (which account for the majority of cases) include destruction of the normal trabecular bone pattern, indistinct margins, and no endosteal bone response. The affected bone is characterized by a mixture of radiodense and radiolucent areas, destruction of the cortex, and periosteal new bone formation, with the formation of Codman triangle (an incomplete response of host periosteal bone)  (<a class="graphic graphic_diagnosticimage graphicRef121738" href="/z/d/graphic/121738.html" rel="external">image 3</a>). The associated soft tissue mass is variably ossified and may be in a radial or "sunburst" pattern  (<a class="graphic graphic_diagnosticimage graphicRef121737" href="/z/d/graphic/121737.html" rel="external">image 4</a>). (See  <a class="medical medical_review" href="/z/d/html/7741.html" rel="external">"Bone tumors: Diagnosis and biopsy techniques", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H1953426474"><span class="h2">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) of the entire length of the involved bone is obtained as part of the initial diagnostic evaluation of suspected osteosarcoma. The MRI protocol should include a T1 coronal sequence.</p><p>In patients with a high clinical suspicion for disease, MRI should be obtained if plain radiographs are unrevealing or have subtle abnormalities. In most cases, MRI is preferred over computed tomography (CT) for the initial evaluation of suspected osteosarcoma, because of its superior definition of soft tissue extension (particularly to the neurovascular bundle), joint and marrow involvement  (<a class="graphic graphic_diagnosticimage graphicRef121738" href="/z/d/graphic/121738.html" rel="external">image 3</a>), and the presence of "skip" metastases [<a href="#rid83">83,85</a>]. (See <a class="local">'Distant metastases'</a> above.)</p><p>For patients with plain radiographic findings characteristic for osteosarcoma, MRI is also indicated for biopsy and surgical planning. MRI should assess the entire length of the involved long bone. MRI with contrast will identify areas in the tumor that are both hypervascular and necrotic, which can assist with subsequent surgical interventions. The use of MRI in the diagnosis of osteosarcoma is similar to that of other bone tumors and is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7741.html" rel="external">"Bone tumors: Diagnosis and biopsy techniques", section on 'Imaging'</a>.)</p><p class="headingAnchor" id="H73785326"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>Alkaline phosphatase [<a href="#rid86">86</a>] and lactate dehydrogenase (LDH) [<a href="#rid87">87</a>] may be obtained as part of the initial diagnostic evaluation. While these labs may be elevated in approximately half of patients with suspected osteosarcoma, they are not routinely used to guide management [<a href="#rid88">88</a>]. Other laboratory evaluations are usually normal. </p><p class="headingAnchor" id="H469559319"><span class="h2">Diagnostic biopsy</span><span class="headingEndMark"> — </span>The diagnosis of osteosarcoma is made definitively with a biopsy and pathologic evaluation of the tumor. While the correct diagnosis can be surmised in up to two-thirds of patients based on clinical presentation and imaging, [<a href="#rid89">89</a>], none of these findings are pathognomonic and a biopsy is still required for confirmation. Once the diagnosis of a primary bone tumor is suspected, patients should be referred to a facility with expertise in the diagnosis (including biopsy) and management of osteosarcoma. (See <a class="local">'Histologic classification'</a> above.)</p><p>Suspected osteosarcoma can be sampled using either a core needle or open biopsy (see  <a class="medical medical_review" href="/z/d/html/7739.html" rel="external">"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management", section on 'Tissue biopsy'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Core needle biopsy </strong>– If a core needle biopsy is planned, the interventional radiologist performing the procedure should communicate with the orthopedic surgeon about the placement of the biopsy tract. The biopsy must be carefully planned to ensure that adequate diagnostic tissue is obtained without compromising future surgical planning, such as biopsy tract removal during definitive surgery or limb salvage procedures [<a href="#rid90">90</a>]. This topic is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7741.html" rel="external">"Bone tumors: Diagnosis and biopsy techniques", section on 'Planning the biopsy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Open biopsy </strong>– If an open biopsy is chosen, the biopsy should be carried out by an orthopedic surgeon who is experienced in the management of osteosarcoma, and ideally, will also be performing the definitive surgery. </p><p></p><p class="headingAnchor" id="H13"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>In patients with suspected osteosarcoma, the primary differential diagnosis includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other malignant bone tumors</strong> – Ewing sarcoma, lymphoma, and distant metastases from other tumors. (See  <a class="medical medical_review" href="/z/d/html/7744.html" rel="external">"Clinical presentation, staging, and prognostic factors of Ewing sarcoma"</a> and  <a class="medical medical_review" href="/z/d/html/6246.html" rel="external">"Overview of Hodgkin lymphoma in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/13940.html" rel="external">"Overview of non-Hodgkin lymphoma in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign bone tumors</strong> – Chondroblastoma, osteoblastoma  (<a class="graphic graphic_diagnosticimage graphicRef98166" href="/z/d/graphic/98166.html" rel="external">image 5</a> and <a class="graphic graphic_diagnosticimage graphicRef98165" href="/z/d/graphic/98165.html" rel="external">image 6</a>), and giant cell tumor of bone (GCTB) may be part of the differential diagnosis of a radiolucent osteosarcoma. (See  <a class="medical medical_review" href="/z/d/html/6294.html" rel="external">"Nonmalignant bone lesions in children and adolescents", section on 'Chondroblastoma'</a> and  <a class="medical medical_review" href="/z/d/html/6294.html" rel="external">"Nonmalignant bone lesions in children and adolescents", section on 'Osteoblastoma'</a> and  <a class="medical medical_review" href="/z/d/html/7731.html" rel="external">"Giant cell tumor of bone"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonneoplastic conditions</strong> – Nonmalignant etiologies such as osteomyelitis, Langerhans cell histiocytosis, and aneurysmal bone cysts may also be included on the differential diagnosis. (See  <a class="medical medical_review" href="/z/d/html/7668.html" rel="external">"Nonvertebral osteomyelitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6294.html" rel="external">"Nonmalignant bone lesions in children and adolescents", section on 'Aneurysmal bone cyst'</a> and  <a class="medical medical_review" href="/z/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Lytic bone lesions'</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">POSTDIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>For patients with a confirmed diagnosis of osteosarcoma, a thorough postdiagnostic evaluation is performed for tumor staging, management (including surgical planning), and prognosis. </p><p class="headingAnchor" id="H1529987005"><span class="h2">Evaluation of primary tumor</span><span class="headingEndMark"> — </span>Upon confirmation of the diagnosis, magnetic resonance imaging (MRI) of the primary tumor should be obtained for staging of the primary tumor, if not obtained prior to biopsy. (See <a class="local">'Magnetic resonance imaging'</a> above.)</p><p class="headingAnchor" id="H15"><span class="h2">Evaluation for systemic disease</span><span class="headingEndMark"> — </span>It is important to assess patients with osteosarcoma for metastatic disease to determine prognosis and treatment. Although prognosis is worse for metastatic disease compared with localized disease, a proportion of patients presenting with metastatic disease may experience long-term survival. (See  <a class="medical medical_review" href="/z/d/html/7723.html" rel="external">"Chemotherapy and radiation therapy in the management of osteosarcoma", section on 'Prognosis and evolution of treatment'</a>.)</p><p>The approach to the staging workup for patients with osteosarcoma is discussed below, which follows guidelines from the National Comprehensive Cancer Network (NCCN) [<a href="#rid91">91</a>], the European Society for Medical Oncology (ESMO) [<a href="#rid92">92</a>], and the Children's Oncology Group Bone Tumor Committee [<a href="#rid93">93</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest computed tomography</strong> – A computed tomography (CT) scan of the chest with contrast should be obtained to evaluate for metastatic disease, as approximately 80 percent of osteosarcoma metastases involve the lungs [<a href="#rid94">94,95</a>]. Histologic confirmation may be obtained for pulmonary lesions that are indeterminate for metastatic disease on imaging. </p><p></p><p class="bulletIndent1">Distinguishing metastatic lesions from benign nodules can be difficult, particularly in adults who have a high prevalence of granulomatous disease and in children living in areas with endemic fungal disease, especially histoplasmosis. (See  <a class="medical medical_review" href="/z/d/html/2451.html" rel="external">"Diagnosis and treatment of pulmonary histoplasmosis", section on 'When to suspect histoplasmosis'</a> and  <a class="medical medical_review" href="/z/d/html/6986.html" rel="external">"Diagnostic evaluation of the incidental pulmonary nodule"</a>.)</p><p></p><p class="bulletIndent1">While calcification can be a sign of benign disease, it may also be seen in metastases from osteosarcoma [<a href="#rid96">96</a>]. Criteria to guide the evaluation of suspected pulmonary metastases are available from the European and American Osteosarcoma Study Group  (<a class="graphic graphic_table graphicRef75576" href="/z/d/graphic/75576.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1">Health care providers should establish the presence of metastatic disease to the lungs at diagnosis using CT and obtain histological confirmation if imaging studies are equivocal. Removal of pulmonary nodules for histologic confirmation can be performed by video-assisted thoracoscopy or open thoracotomy [<a href="#rid97">97</a>]. (See  <a class="medical medical_review" href="/z/d/html/7815.html" rel="external">"Surgical resection of pulmonary metastases: Benefits, indications, preoperative evaluation, and techniques", section on 'Surgical approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positron emission tomography computed tomography</strong> – Whole-body fludeoxyglucose (FDG) positron emission tomography (PET)-CT imaging can be obtained to evaluate for both pulmonary and bone metastases from osteosarcoma [<a href="#rid98">98,99</a>]. In patients with osteosarcoma staged with PET-CT, sensitivity and specificity for the detection of pulmonary metastases is approximately 81 and 94 percent, respectively [<a href="#rid99">99</a>]. For detection of bone metastases, sensitivity and specificity are 93 and 97 percent, respectively. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone scan</strong> – Radionuclide bone scanning with technetium can be obtained with or as an alternative to PET-CT imaging to evaluate for the presence of multiple bone metastatic lesions and "skip" metastases. Both PET-CT and technetium bone scan are adequate studies to detect bone metastases in osteosarcoma, although data are mixed as to which study is more accurate [<a href="#rid100">100-104</a>]. The choice of imaging study may depend on patient or clinician preference or imaging availability at individual institutions.</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Staging</span><span class="headingEndMark"> — </span>There are two staging systems available for osteosarcoma. Regardless of the surgical staging system used, the most significant prognostic indicator remains the presence or absence of distant metastases. Further details on staging system in bone sarcomas are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7739.html" rel="external">"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management", section on 'Tumor staging'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Musculoskeletal Tumor Society staging system</strong> – The Musculoskeletal Tumor Society is a surgical staging system that is most commonly used for bone sarcomas  (<a class="graphic graphic_table graphicRef89014" href="/z/d/graphic/89014.html" rel="external">table 2</a>) [<a href="#rid105">105,106</a>]. This system is based on histologic grade using a two-tiered system (low versus high grade) and whether or not the tumor is confined to a single anatomic compartment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AJCC staging system</strong> – The combined American Joint Committee on Cancer/Union for International Cancer Control tumor, node, and metastasis (TNM) staging system for bone sarcoma is not widely used. The eighth edition contains separate T stage classifications for primary tumors arising in the appendicular skeleton, trunk, skull, and facial bones; those arising in the spine; and those arising in the pelvic bones  (<a class="graphic graphic_table graphicRef110737" href="/z/d/graphic/110737.html" rel="external">table 3</a>) [<a href="#rid107">107</a>]. While there are prognostic stage groupings for tumors arising in the appendicular skeleton, trunk, skull, and facial bones, they do not apply to spine and pelvis tumors.</p><p></p><p class="headingAnchor" id="H252022623"><span class="h2">Fertility counseling</span><span class="headingEndMark"> — </span>Prior to initiating therapy, patients with a diagnosis of osteosarcoma who are of reproductive age may be referred for discussion about fertility preservation options. Further details are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"</a> and  <a class="medical medical_review" href="/z/d/html/121395.html" rel="external">"Fertility preservation: Cryopreservation options"</a>.)</p><p class="headingAnchor" id="H546951281"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/134680.html" rel="external">"Society guideline links: Bone sarcomas"</a>.)</p><p class="headingAnchor" id="H113082609"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83150.html" rel="external">"Patient education: Bone cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29529482"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic characteristics </strong>– Osteosarcoma is a rare primary malignant tumor of bone that is characterized by the production of osteoid (new bone) or immature bone by the malignant cells. Although osteosarcoma is characterized by highly complex karyotypes, there are no specific immunostains or molecular tests that are diagnostic for the disease. (See <a class="local">'Approach to histologic diagnosis'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Osteosarcoma is slightly more predominant in males than females. The bimodal peak incidences are between 13 and 16 years of age and over the age of 65. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong>– Risk factors for osteosarcoma include prior radiation and chemotherapy; Paget disease  (<a class="graphic graphic_diagnosticimage graphicRef55541" href="/z/d/graphic/55541.html" rel="external">image 1</a>) and other benign bone processes; and certain genetic conditions such as hereditary retinoblastoma, Li-Fraumeni syndrome (LFS), and Rothmund-Thomson syndrome (RTS), among others. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic classification </strong>–<strong> </strong>Conventional osteosarcoma accounts for approximately 90 percent of all osteosarcomas. Other less common histologic variants are telangiectatic osteosarcoma, parosteal osteosarcoma, periosteal osteosarcoma, high-grade surface osteosarcoma, and secondary osteosarcoma. (See <a class="local">'Histologic classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>– Osteosarcoma can present with the following findings (see <a class="local">'Clinical presentation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children and adolescents and young adults (AYAs) most frequently present with a primary, sporadic neoplasm located in the metaphyses of the long bones  (<a class="graphic graphic_figure graphicRef76662 graphicRef50795" href="/z/d/graphic/76662.html" rel="external">figure 2A-B</a>). (See <a class="local">'Tumor location'</a> above.)</p><p></p><p class="bulletIndent2">Secondary osteosarcoma (ie, tumor that develops in abnormal bone), subsequent primary osteosarcoma after prior radiation or chemotherapy, and tumors involving the axial and craniofacial bones are primarily observed in adults. (See <a class="local">'Secondary osteosarcoma'</a> above and <a class="local">'Primary versus secondary neoplasms'</a> above and <a class="local">'Radiation and chemotherapy'</a> above and <a class="local">'Tumor location'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients may present with localized, intermittent pain at the primary tumor site of several weeks' duration. Pain may also be related to a pathologic fracture. Systemic symptoms are generally absent. (See <a class="local">'Symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Metastatic disease occurs most frequently in the lungs, followed by the distant bones; patients may also present with "skip" metastases  (<a class="graphic graphic_diagnosticimage graphicRef121740" href="/z/d/graphic/121740.html" rel="external">image 2</a>). (See <a class="local">'Distant metastases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation </strong>–<strong> </strong>The initial diagnostic evaluation includes the following (see <a class="local">'Diagnostic evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A plain radiograph of the primary tumor can demonstrate destructive sclerotic lesions and aggressive periosteal reactions of the bone, such as a Codman triangle  (<a class="graphic graphic_diagnosticimage graphicRef121738" href="/z/d/graphic/121738.html" rel="external">image 3</a>) or a radial or "sunburst" pattern associated with a soft tissue mass  (<a class="graphic graphic_diagnosticimage graphicRef121737" href="/z/d/graphic/121737.html" rel="external">image 4</a>). (See <a class="local">'Plain radiograph'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Magnetic resonance imaging (MRI) with contrast of the entire length of the involved bone can be obtained if plain radiographs are indeterminant. MRI is also indicated for biopsy and surgical planning. (See <a class="local">'Magnetic resonance imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alkaline phosphatase and lactate dehydrogenase (LDH) may be elevated. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of osteosarcoma is made definitively with a biopsy and pathologic evaluation of the tumor, which should ideally be performed at a facility with expertise in the diagnosis and management of osteosarcoma. (See <a class="local">'Diagnostic biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postdiagnostic evaluation </strong>– Once the diagnosis is established, further imaging evaluation should be obtained to complete staging  (<a class="graphic graphic_table graphicRef89014" href="/z/d/graphic/89014.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef110737" href="/z/d/graphic/110737.html" rel="external">table 3</a>) and assess for metastatic disease. (See <a class="local">'Staging'</a> above.)</p><p></p><p class="bulletIndent1">This includes MRI of the entire length of the involved bone (if not obtained prior to biopsy); computed tomography (CT) of the chest with contrast; and fludeoxyglucose (FDG) positron emission tomography (PET)-CT scan and/or radionuclide bone scanning with technetium. (See <a class="local">'Postdiagnostic evaluation'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges Murali Chintagumpala, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Baumhoer D, Böhling TO, Cates JMM, et al. Osteosarcoma. In: WHO Classification of Tumours Soft Tissue and Bone Tumours, 5th ed, The WHO Classification of Tumours Editorial Board (Ed), IARC Press, 2020. p.403.</li><li class="breakAll">Data from the American Cancer Society. Available at: https://www.cancer.org/cancer/osteosarcoma/about/key-statistics.html (Accessed on April 17, 2021).</li><li class="breakAll">Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2018, National Cancer Institute. Bethesda, MD, based on November 2020 SEER data submission, posted to the SEER web site, April 2021. https://seer.cancer.gov/csr/1975_2018/ (Accessed on April 17, 2021).</li><li><a class="nounderline abstract_t">Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009; 152:3.</a></li><li><a class="nounderline abstract_t">Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115:1531.</a></li><li><a class="nounderline abstract_t">Kumar R, Kumar M, Malhotra K, Patel S. Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment. Curr Oncol Rep 2018; 20:13.</a></li><li><a class="nounderline abstract_t">de Pinieux G, Karanian M, Le Loarer F, et al. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS One 2021; 16:e0246958.</a></li><li class="breakAll">Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995 (Pub #99-4649), Ries LA, Smith MAS, Gurney JG, et al (Eds), SEER program, National Cancer Institute, Bethesda, MD 1999. p.99.</li><li class="breakAll">Bleyer A, O’Leary M, Barr R, Ries LAG (eds). Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. NIH Pub. No. 06-5767, National Cancer Institute; Bethesda, MD 2006.</li><li><a class="nounderline abstract_t">Cole S, Gianferante DM, Zhu B, Mirabello L. Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017. Cancer 2022; 128:2107.</a></li><li><a class="nounderline abstract_t">Ward ZJ, Yeh JM, Bhakta N, et al. Estimating the total incidence of global childhood cancer: a simulation-based analysis. Lancet Oncol 2019; 20:483.</a></li><li><a class="nounderline abstract_t">Huvos AG. Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer 1986; 57:1442.</a></li><li><a class="nounderline abstract_t">Nishida Y, Isu K, Ueda T, et al. Osteosarcoma in the elderly over 60 years: a multicenter study by the Japanese Musculoskeletal Oncology Group. J Surg Oncol 2009; 100:48.</a></li><li><a class="nounderline abstract_t">Joo MW, Shin SH, Kang YK, et al. Osteosarcoma in Asian Populations Over the Age of 40 Years: A Multicenter Study. Ann Surg Oncol 2015; 22:3557.</a></li><li><a class="nounderline abstract_t">Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res 2002; :40.</a></li><li><a class="nounderline abstract_t">Grimer RJ, Cannon SR, Taminiau AM, et al. Osteosarcoma over the age of forty. Eur J Cancer 2003; 39:157.</a></li><li><a class="nounderline abstract_t">Hadjipavlou A, Lander P, Srolovitz H, Enker IP. Malignant transformation in Paget disease of bone. Cancer 1992; 70:2802.</a></li><li><a class="nounderline abstract_t">Gennari L, Rendina D, Falchetti A, Merlotti D. Paget's Disease of Bone. Calcif Tissue Int 2019; 104:483.</a></li><li><a class="nounderline abstract_t">Nellissery MJ, Padalecki SS, Brkanac Z, et al. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet 1998; 63:817.</a></li><li><a class="nounderline abstract_t">Mankin HJ, Hornicek FJ. Paget's sarcoma: a historical and outcome review. Clin Orthop Relat Res 2005; 438:97.</a></li><li><a class="nounderline abstract_t">Merchant A, Smielewska M, Patel N, et al. Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone. J Bone Miner Res 2009; 24:484.</a></li><li><a class="nounderline abstract_t">Desai P, Perino G, Present D, Steiner GC. Sarcoma in association with bone infarcts. Report of five cases. Arch Pathol Lab Med 1996; 120:482.</a></li><li><a class="nounderline abstract_t">Smith GD, Chalmers J, McQueen MM. Osteosarcoma arising in relation to an enchondroma. A report of three cases. J Bone Joint Surg Br 1986; 68:315.</a></li><li><a class="nounderline abstract_t">Picci P, Sieberova G, Alberghini M, et al. Late sarcoma development after curettage and bone grafting of benign bone tumors. Eur J Radiol 2011; 77:19.</a></li><li><a class="nounderline abstract_t">Zhang J, Walsh MF, Wu G, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med 2015; 373:2336.</a></li><li><a class="nounderline abstract_t">Mirabello L, Zhu B, Koster R, et al. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncol 2020; 6:724.</a></li><li><a class="nounderline abstract_t">Hauben EI, Arends J, Vandenbroucke JP, et al. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet 2003; 11:611.</a></li><li><a class="nounderline abstract_t">Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours among childhood cancer survivors. Br J Cancer 1987; 56:339.</a></li><li><a class="nounderline abstract_t">Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997; 278:1262.</a></li><li><a class="nounderline abstract_t">Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005; 23:2272.</a></li><li><a class="nounderline abstract_t">Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 2007; 99:24.</a></li><li><a class="nounderline abstract_t">Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48:5358.</a></li><li><a class="nounderline abstract_t">Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250:1233.</a></li><li><a class="nounderline abstract_t">Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992; 326:1301.</a></li><li><a class="nounderline abstract_t">Mirabello L, Yeager M, Mai PL, et al. Germline TP53 variants and susceptibility to osteosarcoma. J Natl Cancer Inst 2015; 107.</a></li><li><a class="nounderline abstract_t">McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994; 12:925.</a></li><li><a class="nounderline abstract_t">Carnevale A, Lieberman E, Cárdenas R. Li-Fraumeni syndrome in pediatric patients with soft tissue sarcoma or osteosarcoma. Arch Med Res 1997; 28:383.</a></li><li><a class="nounderline abstract_t">Wang LL, Levy ML, Lewis RA, et al. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet 2001; 102:11.</a></li><li><a class="nounderline abstract_t">Leonard A, Craft AW, Moss C, Malcolm AJ. Osteogenic sarcoma in the Rothmund-Thomson syndrome. Med Pediatr Oncol 1996; 26:249.</a></li><li><a class="nounderline abstract_t">Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst 2003; 95:669.</a></li><li><a class="nounderline abstract_t">Siitonen HA, Sotkasiira J, Biervliet M, et al. The mutation spectrum in RECQL4 diseases. Eur J Hum Genet 2009; 17:151.</a></li><li><a class="nounderline abstract_t">Mutsaers AJ, Walkley CR. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone 2014; 62:56.</a></li><li><a class="nounderline abstract_t">Sayles LC, Breese MR, Koehne AL, et al. Genome-Informed Targeted Therapy for Osteosarcoma. Cancer Discov 2019; 9:46.</a></li><li><a class="nounderline abstract_t">Cortés-Ciriano I, Lee JJ, Xi R, et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet 2020; 52:331.</a></li><li><a class="nounderline abstract_t">Meltzer PS, Helman LJ. New Horizons in the Treatment of Osteosarcoma. N Engl J Med 2021; 385:2066.</a></li><li><a class="nounderline abstract_t">Chen X, Bahrami A, Pappo A, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 2014; 7:104.</a></li><li><a class="nounderline abstract_t">Cheng L, Pandya PH, Liu E, et al. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma. BMC Med Genomics 2019; 12:23.</a></li><li><a class="nounderline abstract_t">Behjati S, Tarpey PS, Haase K, et al. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat Commun 2017; 8:15936.</a></li><li><a class="nounderline abstract_t">Perry JA, Kiezun A, Tonzi P, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A 2014; 111:E5564.</a></li><li><a class="nounderline abstract_t">Moriarity BS, Otto GM, Rahrmann EP, et al. A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet 2015; 47:615.</a></li><li><a class="nounderline abstract_t">Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer 2014; 14:722.</a></li><li class="breakAll">Gorlick R, Janeway K, Marina N. Osteosarcoma. In: Principles and Practice of Pediatric Oncology, 7th ed, Pizzo PA, Poplack DG (Eds), Lippincott, Williams, and WIlkins, Philadelphia 2016. p.882.</li><li><a class="nounderline abstract_t">Buckley JD, Pendergrass TW, Buckley CM, et al. Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the Children's Cancer Group. Cancer 1998; 83:1440.</a></li><li><a class="nounderline abstract_t">Troisi R, Masters MN, Joshipura K, et al. Perinatal factors, growth and development, and osteosarcoma risk. Br J Cancer 2006; 95:1603.</a></li><li><a class="nounderline abstract_t">Zhang C, Morimoto LM, de Smith AJ, et al. Genetic determinants of childhood and adult height associated with osteosarcoma risk. Cancer 2018; 124:3742.</a></li><li><a class="nounderline abstract_t">Kurt AM, Unni KK, McLeod RA, Pritchard DJ. Low-grade intraosseous osteosarcoma. Cancer 1990; 65:1418.</a></li><li><a class="nounderline abstract_t">Tarkkanen M, Böhling T, Gamberi G, et al. Comparative genomic hybridization of low-grade central osteosarcoma. Mod Pathol 1998; 11:421.</a></li><li><a class="nounderline abstract_t">Malhas AM, Sumathi VP, James SL, et al. Low-grade central osteosarcoma: a difficult condition to diagnose. Sarcoma 2012; 2012:764796.</a></li><li><a class="nounderline abstract_t">Inwards CY, Unni KK. Classification and grading of bone sarcomas. Hematol Oncol Clin North Am 1995; 9:545.</a></li><li class="breakAll">Soft tissue and bone tumours. In: WHO Classification of Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), IARC Press, 2020.</li><li class="breakAll">WHO Classification of Tumorus Editorial Board. Soft tissue and bone tumours. In: WHO Classification of Tumours, 5th ed, IARC Press, 2020. Vol 3.</li><li><a class="nounderline abstract_t">Papagelopoulos PJ, Galanis EC, Vlastou C, et al. Current concepts in the evaluation and treatment of osteosarcoma. Orthopedics 2000; 23:858.</a></li><li class="breakAll">Oliveira AM, Okada K, Squire J. Telangiectatic osteosarcoma. In: WHO classification of tumours of soft tissue and bone, 4th, Fletcher CDM, Bridge JA, Hogendoorn PCW, MErtens F (Eds), IARC, Lyon 2013. p.289.</li><li><a class="nounderline abstract_t">Xu M, Dai N, Yang X, et al. Characteristics and prognosis of telangiectatic osteosarcoma: a population-based study using the Surveillance, Epidemiology and End Results (SEER) database. Ann Transl Med 2021; 9:796.</a></li><li><a class="nounderline abstract_t">Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 2019; 109:36.</a></li><li><a class="nounderline abstract_t">Nakajima H, Sim FH, Bond JR, Unni KK. Small cell osteosarcoma of bone. Review of 72 cases. Cancer 1997; 79:2095.</a></li><li class="breakAll">Kalil RK, Squire J. Small cell osteosarcoma. In: WHO Classification of tumours of soft tissue and bone, 4th, Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (Eds), IARC, Lyon 2013. p.291.</li><li><a class="nounderline abstract_t">Martin SE, Dwyer A, Kissane JM, Costa J. Small-cell osteosarcoma. Cancer 1982; 50:990.</a></li><li><a class="nounderline abstract_t">Stea B, Cavazzana A, Kinsella TJ. Small-cell osteosarcoma: correlation of in vitro and clinical radiation response. Int J Radiat Oncol Biol Phys 1988; 15:1233.</a></li><li><a class="nounderline abstract_t">Sheth DS, Yasko AW, Raymond AK, et al. Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer 1996; 78:2136.</a></li><li><a class="nounderline abstract_t">Okada K, Unni KK, Swee RG, Sim FH. High grade surface osteosarcoma: a clinicopathologic study of 46 cases. Cancer 1999; 85:1044.</a></li><li><a class="nounderline abstract_t">Bertoni F, Bacchini P, Staals EL, Davidovitz P. Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer 2005; 103:2373.</a></li><li><a class="nounderline abstract_t">Cesari M, Alberghini M, Vanel D, et al. Periosteal osteosarcoma: a single-institution experience. Cancer 2011; 117:1731.</a></li><li><a class="nounderline abstract_t">Grimer RJ, Bielack S, Flege S, et al. Periosteal osteosarcoma--a European review of outcome. Eur J Cancer 2005; 41:2806.</a></li><li><a class="nounderline abstract_t">Patel SR. Radiation-induced sarcoma. Curr Treat Options Oncol 2000; 1:258.</a></li><li><a class="nounderline abstract_t">Bacci G, Fabbri N, Balladelli A, et al. Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients. J Bone Joint Surg Br 2006; 88:1071.</a></li><li><a class="nounderline abstract_t">Liang L, Zhang T, You Y, et al. An individual patient data meta-analysis on the effect of chemotherapy on survival in patients with craniofacial osteosarcoma. Head Neck 2019; 41:2016.</a></li><li><a class="nounderline abstract_t">Guadagnolo BA, Zagars GK, Raymond AK, et al. Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment. Cancer 2009; 115:3262.</a></li><li><a class="nounderline abstract_t">Hadley C, Gressot LV, Patel AJ, et al. Osteosarcoma of the cranial vault and skull base in pediatric patients. J Neurosurg Pediatr 2014; 13:380.</a></li><li><a class="nounderline abstract_t">Jasnau S, Meyer U, Potratz J, et al. Craniofacial osteosarcoma Experience of the cooperative German-Austrian-Swiss osteosarcoma study group. Oral Oncol 2008; 44:286.</a></li><li><a class="nounderline abstract_t">Miller BJ, Cram P, Lynch CF, Buckwalter JA. Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database. J Bone Joint Surg Am 2013; 95:e89.</a></li><li><a class="nounderline abstract_t">Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer 2005; 104:1100.</a></li><li><a class="nounderline abstract_t">Sajadi KR, Heck RK, Neel MD, et al. The incidence and prognosis of osteosarcoma skip metastases. Clin Orthop Relat Res 2004; :92.</a></li><li><a class="nounderline abstract_t">Kager L, Zoubek A, Kastner U, et al. Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2006; 24:1535.</a></li><li><a class="nounderline abstract_t">Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology 1997; 202:237.</a></li><li><a class="nounderline abstract_t">Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106:1154.</a></li><li><a class="nounderline abstract_t">Hao H, Chen L, Huang D, et al. Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma. Eur J Cancer Care (Engl) 2017; 26.</a></li><li><a class="nounderline abstract_t">Fu Y, Lan T, Cai H, et al. Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma. Medicine (Baltimore) 2018; 97:e0741.</a></li><li><a class="nounderline abstract_t">Kesselring FO, Penn W. Radiological aspects of 'classic' primary osteosarcoma: value of some radiological investigations: A review. Diagn Imaging 1982; 51:78.</a></li><li><a class="nounderline abstract_t">Peabody TD, Simon MA. Making the diagnosis: keys to a successful biopsy in children with bone and soft-tissue tumors. Orthop Clin North Am 1996; 27:453.</a></li><li class="breakAll">NCCN guidelines available online at https://www.nccn.org/guidelines/category_1 (Accessed on February 07, 2022).</li><li><a class="nounderline abstract_t">Strauss SJ, Frezza AM, Abecassis N, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2021; 32:1520.</a></li><li><a class="nounderline abstract_t">Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51:163.</a></li><li><a class="nounderline abstract_t">Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001; 19:292.</a></li><li><a class="nounderline abstract_t">Jeffree GM, Price CH, Sissons HA. The metastatic patterns of osteosarcoma. Br J Cancer 1975; 32:87.</a></li><li><a class="nounderline abstract_t">Picci P, Vanel D, Briccoli A, et al. Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation. Ann Oncol 2001; 12:1601.</a></li><li><a class="nounderline abstract_t">Lautz TB, Krailo MD, Han R, et al. Current surgical management of children with osteosarcoma and pulmonary metastatic disease: A survey of the American Pediatric Surgical Association. J Pediatr Surg 2021; 56:282.</a></li><li><a class="nounderline abstract_t">Liu F, Zhang Q, Zhu D, et al. Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015; 94:e1462.</a></li><li><a class="nounderline abstract_t">Liu F, Zhang Q, Zhou D, Dong J. Effectiveness of 18F-FDG PET/CT in the diagnosis and staging of osteosarcoma: a meta-analysis of 26 studies. BMC Cancer 2019; 19:323.</a></li><li><a class="nounderline abstract_t">Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000; 27:1305.</a></li><li><a class="nounderline abstract_t">Hurley C, McCarville MB, Shulkin BL, et al. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma. Pediatr Blood Cancer 2016; 63:1381.</a></li><li><a class="nounderline abstract_t">Tal AL, Doshi H, Parkar F, et al. The Utility of 18FDG PET/CT Versus Bone Scan for Identification of Bone Metastases in a Pediatric Sarcoma Population and a Review of the Literature. J Pediatr Hematol Oncol 2021; 43:52.</a></li><li><a class="nounderline abstract_t">Aryal A, Kumar VS, Shamim SA, et al. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma? Clin Orthop Relat Res 2021; 479:1768.</a></li><li><a class="nounderline abstract_t">Byun BH, Kong CB, Lim I, et al. Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma. Skeletal Radiol 2013; 42:1673.</a></li><li><a class="nounderline abstract_t">Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; :9.</a></li><li><a class="nounderline abstract_t">Wolf RE, Enneking WF. The staging and surgery of musculoskeletal neoplasms. Orthop Clin North Am 1996; 27:473.</a></li><li class="breakAll">Kneisl JS, Rosenberg AE, Anderson PM, et al. Bone. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.471.</li></ol></div><div id="topicVersionRevision">Topic 7722 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Baumhoer D, Böhling TO, Cates JMM, et al. Osteosarcoma. In: WHO Classification of Tumours Soft Tissue and Bone Tumours, 5th ed, The WHO Classification of Tumours Editorial Board (Ed), IARC Press, 2020. p.403.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cancer.org/cancer/osteosarcoma/about/key-statistics.html" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Data from the American Cancer Society. Available at: https://www.cancer.org/cancer/osteosarcoma/about/key-statistics.html (Accessed on April 17, 2021).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://seer.cancer.gov/csr/1975_2018/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2018, National Cancer Institute. Bethesda, MD, based on November 2020 SEER data submission, posted to the SEER web site, April 2021. https://seer.cancer.gov/csr/1975_2018/ (Accessed on April 17, 2021).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20213383" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The epidemiology of osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19197972" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29492676" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33630918" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33630918" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33630918" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35226758" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30824204" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Estimating the total incidence of global childhood cancer: a simulation-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2418941" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384906" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Osteosarcoma in the elderly over 60 years: a multicenter study by the Japanese Musculoskeletal Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25676843" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Osteosarcoma in Asian Populations Over the Age of 40 Years: A Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11953594" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Etiology of osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509946" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Osteosarcoma over the age of forty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1451058" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Malignant transformation in Paget disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30671590" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Paget's Disease of Bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9718349" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16131876" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Paget's sarcoma: a historical and outcome review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016598" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8639053" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sarcoma in association with bone infarcts. Report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3457012" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Osteosarcoma arising in relation to an enchondroma. A report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20828957" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Late sarcoma development after curettage and bone grafting of benign bone tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26580448" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Germline Mutations in Predisposition Genes in Pediatric Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32191290" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12891382" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2822073" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Incidence of second primary tumours among childhood cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9333268" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800318" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202110" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3409256" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A cancer family syndrome in twenty-four kindreds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1978757" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1565143" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25896519" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Germline TP53 variants and susceptibility to osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8164043" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9291635" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Li-Fraumeni syndrome in pediatric patients with soft tissue sarcoma or osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11471165" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8600336" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Osteogenic sarcoma in the Rothmund-Thomson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12734318" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18716613" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The mutation spectrum in RECQL4 diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24530473" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30266815" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Genome-Informed Targeted Therapy for Osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32025003" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34818481" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : New Horizons in the Treatment of Osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24703847" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30704460" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28643781" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25512523" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25961939" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25319867" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Translational biology of osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25319867" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Translational biology of osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9762947" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the Children's Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17106438" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Perinatal factors, growth and development, and osteosarcoma risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30311632" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Genetic determinants of childhood and adult height associated with osteosarcoma risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2306687" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Low-grade intraosseous osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9619593" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparative genomic hybridization of low-grade central osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851905" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Low-grade central osteosarcoma: a difficult condition to diagnose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7649942" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Classification and grading of bone sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7649942" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Classification and grading of bone sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7649942" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Classification and grading of bone sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10952054" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Current concepts in the evaluation and treatment of osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10952054" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Current concepts in the evaluation and treatment of osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34268409" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Characteristics and prognosis of telangiectatic osteosarcoma: a population-based study using the Surveillance, Epidemiology and End Results (SEER) database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30685685" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9179055" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Small cell osteosarcoma of bone. Review of 72 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9179055" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Small cell osteosarcoma of bone. Review of 72 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6953993" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Small-cell osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3182355" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Small-cell osteosarcoma: correlation of in vitro and clinical radiation response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8918422" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10091787" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : High grade surface osteosarcoma: a clinicopathologic study of 46 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15852358" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21472720" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Periosteal osteosarcoma: a single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16290134" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Periosteal osteosarcoma--a European review of outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12057168" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Radiation-induced sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877608" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30706580" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : An individual patient data meta-analysis on the effect of chemotherapy on survival in patients with craniofacial osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19382187" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24483254" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Osteosarcoma of the cranial vault and skull base in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17467326" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Craniofacial osteosarcoma Experience of the cooperative German-Austrian-Swiss osteosarcoma study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824394" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16015627" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15346057" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The incidence and prognosis of osteosarcoma skip metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575004" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988217" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421923" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27349943" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29742740" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7042255" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Radiological aspects of 'classic' primary osteosarcoma: value of some radiological investigations: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649728" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Making the diagnosis: keys to a successful biopsy in children with bone and soft-tissue tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649728" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Making the diagnosis: keys to a successful biopsy in children with bone and soft-tissue tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34500044" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18454470" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11338887" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Current treatment of osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1058038" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The metastatic patterns of osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11822761" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33558032" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Current surgical management of children with osteosarcoma and pulmonary metastatic disease: A survey of the American Pediatric Surgical Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26356700" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30953476" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effectiveness of 18F-FDG PET/CT in the diagnosis and staging of osteosarcoma: a meta-analysis of 26 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007511" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27082077" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32815877" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The Utility of 18FDG PET/CT Versus Bone Scan for Identification of Bone Metastases in a Pediatric Sarcoma Population and a Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33635285" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23995264" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3456859" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A system of staging musculoskeletal neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649730" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The staging and surgery of musculoskeletal neoplasms.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
